Tower Research Capital (TRC)’s Connect Biopharma Holdings CNTB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.19K Buy
7,444
+6,562
+744% +$13.4K ﹤0.01% 4421
2026
Q2
$2.1K Buy
+882
New +$2.14K ﹤0.01% 4720
2023
Q1
– Sell
-10,398
Closed -$9K – 5863
2022
Q4
$9K Sell
10,398
-5,812
-36% -$4.79K ﹤0.01% 4177
2022
Q3
$21K Sell
16,210
-615
-4% -$739 ﹤0.01% 3889
2022
Q2
$15K Buy
16,825
+15,584
+1,256% +$23K ﹤0.01% 4061
2022
Q1
$4K Buy
+1,241
New +$5.24K ﹤0.01% 5187

Other funds holding CNTB

Tower Research Capital (TRC)'s CNTB Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Connect Biopharma Holdings (CNTB) stake by 744% in Q3 2026, buying an estimated $13.4K and bringing the position to 7,444 shares worth $8.19K. The position accounts for ﹤0.01% of the portfolio, ranked #4421.

Tower Research Capital (TRC) first reported a position in CNTB in Q1 2022 and has held it in 6 quarters since. The position peaked at $21K in Q3 2022. 53 funds tracked by Wall St. Rank hold CNTB as of Q3 2026.

  • Tower Research Capital (TRC) held 7,444 shares of Connect Biopharma Holdings worth $8.19K as of Q3 2026.
  • Tower Research Capital (TRC) bought 6,562 Connect Biopharma Holdings shares in Q3 2026, an estimated $13.4K.
  • Connect Biopharma Holdings made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4421 holding.
  • Tower Research Capital (TRC) first reported a position in Connect Biopharma Holdings in Q1 2022 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s Connect Biopharma Holdings position peaked at $21K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.